CN111278401B - 递送抗生素大环内酯治疗干眼综合征的组合物和方法 - Google Patents

递送抗生素大环内酯治疗干眼综合征的组合物和方法 Download PDF

Info

Publication number
CN111278401B
CN111278401B CN201880050530.3A CN201880050530A CN111278401B CN 111278401 B CN111278401 B CN 111278401B CN 201880050530 A CN201880050530 A CN 201880050530A CN 111278401 B CN111278401 B CN 111278401B
Authority
CN
China
Prior art keywords
composition
days
tacrolimus
fumed silica
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201880050530.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN111278401A (zh
Inventor
I·阿塔
E·希特里特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eximore Ltd
Original Assignee
Eximore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eximore Ltd filed Critical Eximore Ltd
Publication of CN111278401A publication Critical patent/CN111278401A/zh
Application granted granted Critical
Publication of CN111278401B publication Critical patent/CN111278401B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201880050530.3A 2017-05-30 2018-05-30 递送抗生素大环内酯治疗干眼综合征的组合物和方法 Expired - Fee Related CN111278401B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762512682P 2017-05-30 2017-05-30
US62/512,682 2017-05-30
PCT/IB2018/000693 WO2018220444A2 (en) 2017-05-30 2018-05-30 Compositions and methods for treating dry eye syndrome delivering antibiotic macrolide

Publications (2)

Publication Number Publication Date
CN111278401A CN111278401A (zh) 2020-06-12
CN111278401B true CN111278401B (zh) 2023-08-15

Family

ID=64456159

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880050530.3A Expired - Fee Related CN111278401B (zh) 2017-05-30 2018-05-30 递送抗生素大环内酯治疗干眼综合征的组合物和方法

Country Status (7)

Country Link
US (1) US20200147055A1 (https=)
EP (1) EP3630042A4 (https=)
JP (2) JP7278969B2 (https=)
KR (1) KR20200069261A (https=)
CN (1) CN111278401B (https=)
CA (1) CA3065474A1 (https=)
WO (1) WO2018220444A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022096931A2 (en) * 2020-11-09 2022-05-12 Eximore Ltd. Punctal plugs containing micelle-encapsulated ophthalmic pharmaceuticals and methods for making thereof
WO2024069230A2 (en) * 2022-09-29 2024-04-04 Eximore Ltd. Ophthalmic compositions and methods for sustained drug release

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766242A (en) * 1993-11-15 1998-06-16 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
CN101014317A (zh) * 2004-11-09 2007-08-08 诺瓦加利制药公司 含有免疫抑制剂的眼用乳剂
CN101437478A (zh) * 2004-10-04 2009-05-20 Qlt美国有限公司 聚合送递制剂的眼部送递
CN102144961A (zh) * 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
CN102300517A (zh) * 2008-12-19 2011-12-28 Qlt股份有限公司 物质输送泪点植入物和方法
CN103393483A (zh) * 2006-03-31 2013-11-20 玛提治疗有限公司 用于鼻泪系统的药物释放方法、结构及组合物
CN104884049A (zh) * 2012-11-08 2015-09-02 克莱尔塞德生物医学股份有限公司 用于在人类受试者中治疗眼部疾病的方法和装置
WO2016083891A1 (en) * 2014-11-25 2016-06-02 Eyal Sheetrit Compositions and methods for delivering a bio-active agent or bio-active agents
CN106137528A (zh) * 2010-03-31 2016-11-23 奥库杰克特有限责任公司 用于眼内药物递送的设备和方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU777915B2 (en) * 1999-04-30 2004-11-04 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
JP4974903B2 (ja) * 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物
UY30883A1 (es) * 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
EP2320972B1 (en) * 2008-05-08 2020-07-01 MiniPumps, LLC Implantable drug-delivery devices
CA2798084A1 (en) * 2010-05-17 2011-11-24 Aerie Pharmaceuticals, Inc. Drug delivery devices for delivery of ocular therapeutic agents
ES2727203T3 (es) * 2011-08-29 2019-10-14 Mati Therapeutics Inc Administración por liberación sostenida de agentes activos para tratar glaucoma e hipertensión ocular
MX364310B (es) * 2013-11-05 2019-04-22 Gustavo A Garcia Sanchez Método para preparar una formulación inmunosupresora.

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766242A (en) * 1993-11-15 1998-06-16 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
CN102144961A (zh) * 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
CN101437478A (zh) * 2004-10-04 2009-05-20 Qlt美国有限公司 聚合送递制剂的眼部送递
CN101014317A (zh) * 2004-11-09 2007-08-08 诺瓦加利制药公司 含有免疫抑制剂的眼用乳剂
CN103393483A (zh) * 2006-03-31 2013-11-20 玛提治疗有限公司 用于鼻泪系统的药物释放方法、结构及组合物
CN102300517A (zh) * 2008-12-19 2011-12-28 Qlt股份有限公司 物质输送泪点植入物和方法
CN106137528A (zh) * 2010-03-31 2016-11-23 奥库杰克特有限责任公司 用于眼内药物递送的设备和方法
CN104884049A (zh) * 2012-11-08 2015-09-02 克莱尔塞德生物医学股份有限公司 用于在人类受试者中治疗眼部疾病的方法和装置
WO2016083891A1 (en) * 2014-11-25 2016-06-02 Eyal Sheetrit Compositions and methods for delivering a bio-active agent or bio-active agents

Also Published As

Publication number Publication date
CA3065474A1 (en) 2018-12-06
JP2023113647A (ja) 2023-08-16
JP7278969B2 (ja) 2023-05-22
WO2018220444A2 (en) 2018-12-06
US20200147055A1 (en) 2020-05-14
EP3630042A2 (en) 2020-04-08
JP7682226B2 (ja) 2025-05-23
JP2020521790A (ja) 2020-07-27
CN111278401A (zh) 2020-06-12
EP3630042A4 (en) 2021-06-23
KR20200069261A (ko) 2020-06-16
WO2018220444A3 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
US12318394B2 (en) Devices and methods for delivering a bio-active agent or bio-active agents
JP7682226B2 (ja) ドライアイ症候群を治療するための抗生物質マクロライドを送達する組成物および方法
JP5858906B2 (ja) 多孔質シリコン薬物溶出粒子
KR102456032B1 (ko) 눈에서 지속적 약물 방출을 달성하기 위한 방법 및 생체적합성 조성물
KR20030009447A (ko) 지속 방출 약물 전달 장치, 그의 사용 방법 및 그의 제조방법
EP3233058A1 (en) Sunitinib formulations and methods for use thereof in treatment of glaucoma
JPH06505274A (ja) 持続性放出医薬デリバリー装置
JP2010538696A (ja) 治療薬剤の持続放出のための薬物コア
KR102004014B1 (ko) 약물 전달 시스템
US20100040672A1 (en) Delivery of therapeutics
EP3154524A1 (en) Extended-release drug delivery compositions
WO2024069230A2 (en) Ophthalmic compositions and methods for sustained drug release
HK1235660B (en) Methods and biocompatible compositions to achieve sustained drug release in the eye

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20230815